SCHEMBL6316428

SCHEMBL6316428

Cc1ccc(-c2noc(N)c2C(=O)NC2CCCC2)o1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.51
HPGD P15428 2/20 0.51
KMT2A Q03164 2/20 0.47
RAB9A P51151 7/20 0.45
NPC1 O15118 6/20 0.45
S1PR1 P21453 2/20 0.44
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 2/20 0.42
POLB P06746 1/20 0.42
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41
CA7 P43166 1/20 0.41
TAS1R3 Q7RTX0 2/20 0.41
TAS1R1 Q7RTX1 2/20 0.41
TAS1R2 Q8TE23 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
TSHR P16473 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6321764 0.99 SMN1; SMN2 (0.53) SMN1; SMN2HPGDKMT2ARAB9ANPC1
SCHEMBL6316098 0.99 SMN1; SMN2 (0.53) SMN1; SMN2HPGDKMT2ARAB9ANPC1
SCHEMBL6320687 0.98 SMN1; SMN2 (0.48) SMN1; SMN2HPGDKMT2ARAB9ANPC1
SCHEMBL6315521 0.87 TAS1R3 (0.46) POLBTAS1R3TAS1R1TAS1R2
SCHEMBL6314776 0.86 CA1 (0.56) KMT2ARAB9ANPC1S1PR1MEN1
SCHEMBL6318801 0.85 CA1 (0.55) KMT2ARAB9ANPC1S1PR1MEN1
SCHEMBL6323196 0.85 CA1 (0.55) KMT2ARAB9ANPC1S1PR1MEN1
SCHEMBL6316229 0.84 LMNA (0.46) SMN1; SMN2HPGDKMT2ARAB9AMEN1
SCHEMBL6315957 0.84 CA1 (0.56) KMT2ARAB9ANPC1MEN1CA1
SCHEMBL6318857 0.83 NPSR1 (0.42) SMN1; SMN2HPGDKMT2ARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 SMN1; SMN2 2766/4885HPGD 2923/4885KMT2A 1089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.